Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma

Abstract

Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma.